Steven Cohen's NMRA Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 602,403 shares of Neumora Therapeutics, Inc. (NMRA) worth $1.17 M, representing 0.00% of the portfolio. First purchased in 2024-Q3, this short-term holding has been held for 4 quarters.
Based on 13F filings, Steven Cohen has maintained this position in NMRA for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 3.67 M shares. Largest reduction occurred in Q1 2026, reducing 3.07 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Neumora Therapeutics (NMRA) Holding Value Over Time
Track share changes against reported price movement
Quarterly Neumora Therapeutics (NMRA) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -3.07 M | Reduce 83.60% | 602,403 | $1.95 |
| Q4 2025 | +3.67 M | New Buy | 3.67 M | $1.79 |
| Q4 2024 | -83,077 | Sold Out | 0 | $0.00 |
| Q3 2024 | +83,077 | New Buy | 83,077 | $13.21 |
Steven Cohen's Neumora Therapeutics Investment FAQs
Steven Cohen first purchased Neumora Therapeutics, Inc. (NMRA) in Q3 2024, acquiring 83,077 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Neumora Therapeutics, Inc. (NMRA) for 4 quarters since Q3 2024.
Steven Cohen's largest addition to Neumora Therapeutics, Inc. (NMRA) was in Q4 2025, adding 3,673,839 shares worth $6.58 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 602,403 shares of Neumora Therapeutics, Inc. (NMRA), valued at approximately $1.17 M.
As of the Q1 2026 filing, Neumora Therapeutics, Inc. (NMRA) represents approximately 0.00% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Neumora Therapeutics, Inc. (NMRA) was 3,673,839 shares, as reported at the end of Q4 2025.